
Benjamin G Carlisle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1904461/publications.pdf Version: 2024-02-01



RENIAMIN C. CADUSIE

| # | Article | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov. PLoS ONE, 2022, 17, e0262114. | 1.1 | 7 |
| 2 | Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers. Clinical Trials, 2022, 19, 337-346. | 0.7 | 6 |
| 3 | Analysis of clinical trial registry entry histories using the novel R package cthist. PLoS ONE, 2022, 17, e0270909. | 1.1 | 6 |
| 4 | Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration. JAMA Network Open, 2021, 4, e2110456. | 2.8 | 10 |
| 5 | Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials, 2020, 17, 18-29. | 0.7 | 5 |
| 6 | Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer. Journal of the National Cancer Institute, 2020, 112, 859-862. | 3.0 | 2 |
| 7 | Imatinib and the long tail of targeted drug development. Nature Reviews Clinical Oncology, 2020, 17, 1-3. | 12.5 | 24 |
| 8 | Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study. BMJ Open, 2020, 10, e034306. | 0.8 | 6 |
| 9 | How well are Phase 2 cancer trial publications supported by preclinical efficacy evidence?. International Journal of Cancer, 2019, 145, 3370-3375. | 2.3 | 4 |
| 10 | Trials that say "maybe― the disconnect between exploratory and confirmatory testing after drug approval. BMJ: British Medical Journal, 2018, 360, k959. | 2.4 | 14 |
| 11 | Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections. JAMA - Journal of the American Medical Association, 2017, 318, 1003. | 3.8 | 8 |
| 12 | Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biology, 2017, 15, e2000487. | 2.6 | 33 |
| 13 | Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. Journal of the National Cancer Institute, 2016, 108, . | 3.0 | 46 |
| 14 | Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials. BMJ, The, 2015, 350, h1116-h1116. | 3.0 | 26 |
| 15 | Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clinical Trials, 2015, 12, 77-83. | 0.7 | 244 |
| 16 | Rethinking Research Ethics: The Case of Postmarketing Trials. Science, 2012, 336, 544-545. | 6.0 | 32 |